Novartis: Remibrutinib Just Passed the Test Its Whole Drug Class Kept Failing

Novartis shares jumped about 6% on Tuesday, the kind of single-day move a $300 billion drugmaker almost never makes without something real behind it. The trigger: remibrutinib, an oral pill, met its main goal in two Phase 3 trials in relapsing multiple sclerosis, beating an older rival treatment on every measure that mattered. Investors didn't need the headline explained — they already knew this drug. It has been approved since last fall as Rhapsido, the first oral targeted treatment for a stubborn form of chronic hives. Tuesday's results are what turn it from a single-indication product into the thing the growth plan has rested a big part of its credibility on: a genuine multi-billion-dollar, multi-disease franchise. The question is whether the 6% move is the market finally crediting that — or paying up before the evidence is complete.

The two trials, REMODEL-1 and REMODEL-2, are near-identical: about 2,000 people with relapsing MS — the form where the disease comes in unpredictable attacks — were randomized to remibrutinib 100 mg or teriflunomide, an older MS pill, in a double-blind study that ran up to 30 months. Remibrutinib cut the annual relapse rate more than teriflunomide and came out ahead on all of the pre-specified secondary endpoints, including new brain lesions, with a clinically meaningful delay in disability progression. Novartis also emphasized no liver safety signal and no cases meeting Hy's Law criteria — the strictest test for serious drug-induced liver injury.

Notice what Tuesday's release did not give you: the actual relapse-reduction percentages. Those figures come later, in a fuller presentation at the international MS meeting in Toronto, ahead of the plan to file the drug for approval worldwide. The stock moved 6% on the pass, not on the magnitude.

That liver detail is not boilerplate; it is the fact that separates this readout from every other drug in its class. Remibrutinib is a Bruton's tyrosine kinase inhibitor — it blocks an enzyme that drives the immune cells responsible for MS attacks and hives alike. The class was supposed to be the next advance in MS: a high-efficacy pill with no injections. The past several years have been defined by failure. Merck KGaA's evobrutinib could not beat teriflunomide in Phase 3 and was dropped. Sanofi's tolebrutinib missed its goals in relapsing MS and carries a liver-safety shadow dating back to a 2022 regulatory hold. Roche's fenebrutinib actually worked — cutting relapses 51% and 59% versus teriflunomide across its two Phase 3 studies — but then had to walk back expectations after disclosing a death imbalance in those same trials.

Remibrutinib enters this group already holding an approved label. Regulators signed off on it for chronic spontaneous urticaria in September 2025, and the development program now spans more than 4,500 patients across indications. In a class whose failure mode is "doesn't work" or "damages the liver," clearing both gates with a clean safety record is exactly the evidence that de-risks an asset rather than merely advancing it. That is what the market paid for.

The commercial stakes deserve the same plain language. Global MS drug sales run roughly $30 billion a year by current estimates and keep growing, and the appeal of the BTK class was always the oral segment — patients who want high efficacy without infusions or regular monitoring. And MS is not remibrutinib's only arrow. As Rhapsido, it addresses the roughly 1.7 million Americans living with chronic spontaneous urticaria, and this year's treatment guidelines now recommend it. It won a Phase 3 trial in a second form of hives in February; it has Phase 2 data in peanut allergy with a Phase 3 program due to start this year; and Phase 3 studies in myasthenia gravis and progressive MS are running. Reuters reports analysts see up to $9 billion in peak annual sales across all of these indications, and brackets remibrutinib with two other pipeline drugs — the cholesterol medicine pelacarsen and the genetic therapy del-desiran — as carrying more than $10 billion in combined peak-sales potential.

Now put that next to where the stock has been. Novartis guides to 5-6% annual sales growth through 2030, built on eight already-launched drugs with big-blockbuster potential and a pipeline of more than 30 assets. But the near-term numbers have looked like a no-growth story: first-quarter sales fell 5% as U.S. generics crushed the heart drug Entresto, and the second quarter crawled back to just 1% growth even as five priority brands — Kisqali, Kesimpta, Scemblix, Pluvicto and Leqvio — grew by 32% to 89%. Entresto alone fell roughly half. A company with operating margins around 30%, roughly $15 billion of annual free cash flow, a close-to-2% dividend and 19 straight years of dividend payments deserves a defensive multiple — and gets one, at about 20x forward earnings. What that multiple does not price in is the pipeline. Remibrutinib is the most credible version of that claim: already commercial, already winning trials, and now with its largest addressable market de-risked.

Tuesday's pop does not make this a slam dunk, and it is worth saying plainly. First, teriflunomide is a modest, aging rival; beating it — as Roche's fenebrutinib also did — is the entry ticket, not proof of dominance. The top of the MS market belongs to the high-efficacy injectables, above all Ocrevus and Novartis's own Kesimpta, which is growing 32% and is one of the company's biggest growth engines. If remibrutinib mostly pulls patients from Kesimpta, Novartis is trading revenue between its own products — better to own both options than hand the category to Roche, but that is rotation, not fresh growth. Second, the magnitude question is genuinely open. If Toronto shows relapse reductions well below fenebrutinib's 51-59%, Tuesday's enthusiasm will look premature.

And the entry point has changed. Before this week, the disconnect — a flat-looking base business versus a growth plan the market hadn't finished crediting — was visible. At about $161 a share, up 17% year-to-date and within a few percent of a 52-week high, that gap has narrowed. With the S&P 500 up about 12% this year and near records, the market is in a phase that rewards proof over promise — and Tuesday was a substantial piece of proof.

What revises the view either way is now concrete and observable. The Toronto presentation will deliver the relapse-reduction magnitude and a deeper safety read in a 2,000-patient population. Filings, a label, and then reimbursement behavior in a market dominated by entrenched injectables will decide whether $9 billion of peak-sales potential is pipeline talk or a plan. I would not chase the pop — the compelling price was the pre-gap one. But the direction of the evidence is unambiguous: in a drug class that has spent years breaking its own promises, remibrutinib is the one that keeps keeping them.